Final results from the PALOMA 3 study show that addition of palbociclib to fulvestrant improves overall survival by 7 months, but the result was not statistically significant. So now what?
Medscape Medical News
This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.